Drugs / MT101-5
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05844787 | Jul 2022 → Feb 2023 | Parkinson disease | Mthera Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06175767 | Mar → Jul 2025 overdue | Parkinson disease | Mthera Pharma Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT101-5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05844787 ↗ |
| Route | Oral | “the randomly assigned dose of MT101-5 or placebo will be administered as oral tablet” NCT05844787 ↗ |